Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients

Salem, Hiam; Morcos, Nadia Y. S.; Doss, Wahid; Makhlouf, Mohamed; El Atrebi, Kamal; Saleh, Eman

doi:10.21608/ejaps.2022.125337.1026

Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients

Document Type : Original Article

Authors

¹ Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt

² Tropical Medicine and Hepatology Department, Faculty of Medicine, Cairo university, Giza, Egypt

³ Internal Medicine Department, Faculty of Medicine, Ain shams university, Cairo, Egypt

⁴ National Hepatology and Tropical Medicine Research Institute, Egypt

10.21608/ejaps.2022.125337.1026

Abstract

Even though Sofosbuvir (SOF) has revolutionized the treatment of chronicHCV infection, treatment with pegylated interferon in combination with Ribavirin isconsidered the standard of care for treatment in many countries. Aim: This study aimedto monitor the efficacy and safety of SOF/RBV with or without Peg-INF-α-2a, inEgyptian patients with chronic HCV genotype 4. Subjects: 165 patients infected withHCV-GT4 were enrolled in this prospective study. Eligible patients received therecommended doses of SOF/RBV for 24 weeks (Dual treatment) or SOF/RBV/Peg-IFN-α-2a for 12 weeks (Triple treatment). All patients were followed up for 24 weeks afterthe end of therapy. Results: The highest SVR24 rates were attained with the Triple groupcorresponding to the Dual group. Patients who failed to treatment, had higher baselinePDGF in both groups, TNF-α in the Dual group, and lower TSH in the Triple group.Adverse effects included a decrease in hemoglobin and WBCs with an increase increatinine, ferritin and TSH. The favorable effects included normalization of liverindices, correction of hypolipidemia, together with a decrease in TNF-α. Moreover, thecurrent study showed the overall frequency of IL28B genotypes was 100% for genotypeCT. Results: Results of SOF-based therapies achieved better SVR24 rates with theaddition of Peg-INF-α-2a.

Keywords